The clinical pharmacologist: An endangered species?*

Vestal, Robert E.

doi:10.1016/s0009-9236(98)90129-1

Cited by 4 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1978 there were 16 training programs and 55 training slots for clinical pharmacologists in the United States, but by 1992 there were only eight programs and 35 training slots, the latter declining to 28 slots by 1996. These numbers, the impact and long-term consequences of this decline in training positions, and the role of the subject in the medical school curriculum have been discussed in two recent publications from past presidents of the American Society for Clinical Pharmacology and Therapeutics (29,30).…”

Section: The Decline Of Clinical Pharmacology Education In the Unitedmentioning

confidence: 99%

Pharmacovigilance: Three Suggestions for Improving the Quantity and Quality of Adverse Event Reports

Burt

2000

Drug Information J

View full text Add to dashboard Cite

Pharmacovigilance is intended to provide early detection of warning signals to minimize the impact and spread of adverse drug reactions. For the system to be effective, there must be rapid reporting of adverse events to a central reviewfunction which must quickly recognize the signals and act upon them. Both the quantity and the quality of adverse event reports must be improved. Education in clinical pharmacology should be restored to prominence in the medical school curriculum. Prescribers and those who care for patients need to understand the purpose of a central reporting system and be encouraged to file complete reports. Collaboration between the medical profession, pharmaceutical companies, and regulatory agencies is required i f improvements in the quantity and quality of adverse event reports are to appea,:

show abstract

Section: The Decline Of Clinical Pharmacology Education In the Unitedmentioning

confidence: 99%

Pharmacovigilance: Three Suggestions for Improving the Quantity and Quality of Adverse Event Reports

Burt

2000

Drug Information J

View full text Add to dashboard Cite

show abstract

“…In case some of the readers are bemused by this description, they need not feel guilty of ignorance, for we indeed belong to an endangered species. This description is originally not ours and has been borrowed (Vestal, 1998). Unlike our other super speciality brethren such as cardiologists, gastroenterologists, nephrologists etc who are virtually omnipresent, we are conspicuous by our near absence.…”

Section: Introductionmentioning

confidence: 99%

What clinical pharmacology means to us

Malhotra¹,

Shafiq²

2006

Mens Sana Monogr

View full text Add to dashboard Cite

Clinical Pharmacology is a specialty with many attributes and our association with the subject has allowed us to acquire, apply and disseminate myriad aspects of research and practice. Though clinical pharmacologists are conspicuous by virtue of their small number, recent years have shown a growing need for the course. In the review below we navigate through several aspects of the subject as we encountered them from time to time. From critical appraisal of literature, to application of knowledge of drugs, to clinical practice; moving on to clinical and basic research, to drug development process, to policy making - these are but a few of the many fields which constitute the scope of clinical pharmacology. The importance of the subject lies in allowing a trainee to develop a broad overview of the entire process, from drug generation to drug distribution to drug utilization, a process meant for the greater common goal of better health for all. We foresee a bright future for the subject though with a slight skepticism thrown in. In the present article, we make use of personal experiences and reference from literature to help you get a broad view of what clinical pharmacology means to us.

show abstract

“…The expertise required on such committees and their composition, roles, powers, responsibilities, reimbursement, and oversight have not yet been well defined and will vary according to the risk and design of a study. The logistics are daunting when one considers the number of protocols at large institutions performing research that will require monitoring by such committees, as well as the fact that the members likely to be best qualified—clinical researchers and clinical pharmacologists—are in short supply and face many other career demands 2 , 11 , 12 , 13 …”

mentioning

confidence: 99%

“…The logistics are daunting when one considers the number of protocols at large institutions performing research that will require monitoring by such committees, as well as the fact that the members likely to be best qualified-clinical researchers and clinical pharmacologists-are in short supply and face many other career demands. 2,[11][12][13] How will such a committee deal with the occurrence of an uncommon but potentially serious adverse event in a healthy individual in a small study? This same question faces all researchers who perform studies and those who oversee the safety of subjects participating in research: What degree of risk is acceptable and how do we deal with it?…”

mentioning

confidence: 99%